A single-arm, open-label clinical trial to evaluate the safety, efficacy and pharmacokinetics of TAP-1503 cream in patients with atopic dermatitis aged 3 to 24 months.

Start Date18 Apr 2025

Sponsor / Collaborator

Peking University People's Hospital

NCT06742957

/ RecruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site, Clinical Study to Evaluate the Therapeutic Equivalence of Tapinarof Cream 1% (Teva Pharmaceuticals, Inc.) with VTAMA® Tapinarof (Tapinarof) Cream 1% (Dermavant Sciences, Inc.) in Adult Patients with Plaque Psoriasis

To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.

Start Date17 Dec 2024

Sponsor / Collaborator

Teva Pharmaceuticals USA, Inc.

[+1]

NCT06661213

/ Not yet recruitingEarly Phase 1IIT

Tapinarof for Cutaneous Lupus Erythematosus

We hypothesize that topical application of Tapinarof, an FDA-approved topical Aryl hydrocarbon receptor (AHR) agonist for the treatment of plaque psoriasis, would inhibit lupus-causing T cells and lead to improvement of cutaneous lupus lesions. To test this hypothesis, we will perform a prospective, interventional clinical trial in patients with chronic and/or subacute cutaneous lupus. This trial will include outcomes analyzing the change in cutaneous lupus lesions using standardized assessments, but also analyze pre- and post-treatment skin and blood immune parameters to elucidate the immune effects and changes in lupus as a result of topical AHR agonist application. The goals are to 1) identify if topical AHR agonism leads to improvement in cutaneous lupus, and 2) examine the immunopathology of cutaneous lupus and its alteration with topical AHR agonist treatment.

Start Date01 Dec 2024

Sponsor / Collaborator

Northwestern University

100 Clinical Results associated with Benvitimod

100 Translational Medicine associated with Benvitimod

100 Patents (Medical) associated with Benvitimod

451

Literatures (Medical) associated with Benvitimod

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials

Article

Author: Rubenstein, David S. ; Gold, Linda Stein ; Piscitelli, Stephen C. ; Ehst, Benjamin D. ; Green, Lawrence J. ; Zirwas, Matthew J. ; Del Rosso, James ; Brown, Philip M. ; Tallman, Anna M.

Background: Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes.Methods: Patients received Tapinarof or vehicle cream QD for 8 weeks. Tolerability was evaluated using patient/parent/caregiver and investigator 5-point Local Tolerability Scales (LTS). Investigators assessed tolerability for sensitive skin areas, including face/neck.Results: 813 patients were randomized (∼80% pediatric). Mean pretreatment baseline overall LTS scores were similar across groups and trials: 1.0-1.9 (patient-assessed) indicating slight burning/stinging and itching; and 0.3-0.6 (investigator-assessed) indicating no-to-minimal irritation. Tapinarof was well tolerated with improvement from pretreatment baseline and no-to-minimal burning/stinging and itching from first application through Week 8 (patient-reported): mean Week 8 LTS scores were 0.2-0.4 (burning/stinging) and 0.6-0.8 (itching). Investigators reported improvement from pretreatment baseline with no-to-minimal irritation (dryness/erythema/peeling) from first Tapinarof application through Week 8 (mean LTS scores: 0.2 and 0.1 in ADORING 1 and 2, respectively). Across sensitive skin, investigators reported no-to-minimal irritation from first application through Week 8 (mean scores [Tapinarof versus vehicle]: 0-0.3 versus 0-1.0).Conclusion: Tapinarof was well tolerated locally from first application through Week 8, including on sensitive skin areas.Clinicaltrials.gov numbers NCT05014568, NCT05032859.

26 Mar 2025·CLINICAL AND EXPERIMENTAL DERMATOLOGY

Itching for innovation: the role of aryl hydrocarbon receptor agonists as a future therapy for atopic dermatitis

Review

Author: O’Toole, Edel A ; Wazir, Areen

Abstract:

Atopic dermatitis (AD) is a chronic, inflammatory skin condition that affects over 200 million people worldwide. Patients commonly present with dry, itchy and sore skin. The challenge in finding optimal treatment for AD stems from the heterogeneous nature of the disease and its multifaceted aetiology: skin barrier dysfunction, immune system dysregulation, genetic factors, environmental factors and alterations in skin microorganisms. Traditional treatments for AD, such as corticosteroids, calcineurin inhibitors and immunosuppressants, have several limitations, such as the reoccurrence of symptoms when discontinued, lack of targeted action and risk of adverse effects. The aim of this literature review was to explore and summarize the role of aryl hydrocarbon receptor (AHR) agonists (namely tapinarof) as potential future therapy for AD. It is hoped that AHR agonists will overcome the limitations of traditional AD therapies and exert their therapeutic value by maintaining the integrity of the skin barrier, defending against oxidative stress, modulating immune activity and inflammation and restoring a healthy skin microbiome. Tapinarof, a topical AHR agonist, is showing promising results and has recently concluded its long-term extension phase III trial (ADORING 3). For tapinarof to be integrated into the AD treatment pathway, robust research evidence must be presented on its efficacy, durability, potential remittive effect and safety across different AD subtypes in a large, diverse patient population. In addition, the cost-effectiveness of tapinarof compared with its topical counterparts needs to be considered and multidisciplinary collaboration is required between researchers, clinicians and policymakers.

01 Mar 2025·ARCHIV DER PHARMAZIE

Biginelli dihydropyrimidines and their acetylated derivatives as L‐/T‐type calcium channel blockers: Synthesis, enantioseparation, and molecular modeling studies

Article

Author: Zamponi, Gerald W. ; Gündüz, Miyase Gözde ; Lee, J. T. ; Wolber, Gerhard ; Huang, Sun ; Dengiz, Cagatay ; Armstrong, Daniel W. ; Nafie, Jordan W. ; Denzinger, Katrin

Abstract:

Biginelli dihydropyrimidines (DHPMs) are considered superior over 1,4‐dihydropyridines (DHPs) in terms of both light and metabolic stabilities. Nevertheless, DHPs dominate the market as the most prescribed calcium channel blockers with strong therapeutic potential in managing cardiovascular ailments. To overcome the restrictions that complicate the formulation and postadministration of DHPs, employing bioisosteric replacement by exchanging the DHP ring with DHPM appears as a logical approach for the improved formulations of new calcium channel blockers. In this study, we obtained DHPM derivatives via Biginelli synthesis and acetylated their N‐3 position by heating them in acetic anhydride (GD1–GD12). We also incorporated the DHPM scaffold into a condensed ring system (GD13 and GD14). These DHPMs were evaluated for their ability to block both L‐ (Cav1.2) and T‐ (Cav3.2) type calcium channels. Compounds carrying acetyl moiety on the N‐3 position of the DHPM scaffold appeared to be more effective inhibitors of both channels. Retesting GD4 enantiomers, separated using high‐performance liquid chromatography (HPLC) on a chiral stationary phase, revealed that the (R)‐isomer predominantly contributes to the outstanding inhibitory activity of GD4 on calcium channels. Molecular modeling studies, including docking, molecular dynamics simulations, and dynophore analysis, provided insights into the binding mechanism of DHPMs to Cav1.2 and Cav3.2, for the first time.

125

News (Medical) associated with Benvitimod

11 Apr 2025

·www.globenewswire.com

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces the filing of two groundbreaking patents for tapinarof (VTAMA®), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone. This innovative approach differentiates Conduit's intellectual property from existing formulation patents, offering potential partners a next generation tapinarof asset with what the Company estimates to be extensive commercial viability. This comes at a critical juncture for VTAMA®, a drug that has demonstrated blockbuster potential through Organon's $1.2 billion acquisition from Dermavant Sciences yet could face imminent generic competition upon exclusivity expiry in 2027. The timing is particularly strategic in the Company’s view, with tapinarof now entering clinical trials for cutaneous lupus and showing promise across multiple other inflammatory and autoimmune indications. Conduit's novel approach could enable an even broader range of high-value therapeutic opportunities, positioning Conduit at the forefront of a rapidly growing market segment. Conduit believes this new IP could enable formulations of tapinarof that address three key market needs: improved patient tolerability, extended patent protection, and expanded therapeutic applications. The global market for anti-inflammatory therapies, projected to exceed $233.6 billion by 2032 presents significant growth potential as tapinarof’s mechanism of action shows increasing relevance across numerous inflammatory conditions. By cocrystallizing Tapinarof with a therapeutic agent specifically selected to address unmet patient needs, Conduit has created an asset that combines potential clinical benefits with strong intellectual property protection during the crucial window before generic market entry, while simultaneously positioning the Company in the larger inflammatory/autoimmune space. The addition of this new asset to Conduit's portfolio reinforces the Company's business model of identifying and enhancing clinically validated compounds with high commercial potential. This approach previously yielded success with Conduit's development of AZD1656 for autoimmune diseases and continues to drive the Company's pipeline strategy. With the anti-inflammatory therapeutics market as a whole growing at nearly 9% annually and dermatology treatments maintaining 6-8% growth through 2030, Conduit believes a new patent protected tapinarof product represents a unique opportunity for partners seeking to exploit the full potential of the drug by both maximising its position in the dermatology space alongside expanding its market into other high value disease areas with current unmet needs. "With this strategic addition to our portfolio, we are not just adding another asset, but adding what we believe to be a highly commercially valuable patent position for tapinarof," said Dr. Joanne Holland, Chief Scientific Officer of Conduit Pharmaceuticals. "Whilst the current formulation is focused purely on underlying disease, our tapinarof cocrystal aims to offer a multifaceted approach addressing patient symptoms as well as disease. New composition of matter IP, on a drug that could imminently face generic competition on near-term exclusivity expiry, could offer partners a strong position to exploit its market potential in the wider inflammatory and autoimmune space. We are now actively pursuing partnerships that can leverage this breakthrough IP while we continue to advance our broader pipeline." About Conduit Pharmaceuticals Conduit is a multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations. Investors & Media:info@conduitpharma.com

AcquisitionDrug ApprovalPatent Expiration

19 Mar 2025

·www.drugs.com

American Academy of Dermatology, March 7 to 11

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health professionals, and others interested in dermatology. The conference highlighted recent advances in the diagnosis and management of dermatological conditions. During one presentation, Joshua Cook, M.D., of the Columbia University Irving Medical Center in New York City, noted that targeting insulin resistance and hyperinsulinemia is important not only for the treatment of obesity and diabetes, but potentially also independently for improving metabolism-related inflammatory skin diseases like psoriasis and hidradenitis suppurativa. Cook discussed the tight epidemiologic connection between obesity, type 2 diabetes, and inflammatory skin diseases, especially psoriasis. The mechanistic basis of this connection is likely due to insulin resistance and/or hyperinsulinemia. Cook noted that hyperinsulinemia likely drives excessive proliferation and inflammation of skin lesions in psoriasis and other inflammatory skin diseases, even in the setting of systemic insulin resistance. "We are currently performing clinical studies to better understand the role of insulin action in psoriasis," Cook said. "Health care providers should strongly consider screening patients with overweight/obesity and inflammatory skin diseases with hemoglobin A1c, fasting glucose, and lipid profiles. Treatment of obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists may improve inflammatory skin disease activity (an area of active research). There may also be roles for metformin and pioglitazone in inflammatory skin disease treatment in select patients." Abstract During another presentation, Daniel Charles Butler, M.D., of the University of Arizona College of Medicine in Tucson, discussed the connection between itch and aging. Butler discussed how itch is very common in the older adult population. He noted there are many etiologic contributors to itch, including the immune system, the skin barrier, and the cutaneous nerves, all of which are uniquely impacted by aging. "As practicing clinicians, we need to substantiate itch as a real, impactful but targetable symptom and disease," Butler said. "The connection between age and itching allows us to target contributing etiologies with available treatments. For example, itch in older adults is often multifactorial with immunologic changes and neuropathic changes. This allows us to use treatment to target multiple contributors." Butler disclosed financial ties to the pharmaceutical industry. Abstract Adam J. Friedman, M.D., of the George Washington School of Medicine and Health Sciences in Washington, D.C., discussed how food allergy is an extremely rare cause of chronic urticaria with no identifiable cause (CSU), and some food intolerances may contribute, but responses are highly individualized and elimination diets should only be done in a structured way. Friedman provided insight into how urticaria, both acute and chronic, is a common condition, affecting as many as 80 percent of people at some point in their lives. For approximately 1 percent of individuals who develop chronic urticaria, this condition can last for years, significantly impacting quality of life. While patients often search for a clear trigger, more than two-thirds of cases occur without an identifiable cause. Although food allergies can trigger acute urticaria, particularly in children, when it comes to CSU, food allergy is rarely a culprit. Friedman noted that, instead, he often sees food intolerances or pseudoallergic reactions, which may contribute to symptoms in some individuals. This distinction is important because a true food allergy involves an immune response, and food intolerances tend to be more variable, harder to predict, and less understood. A number of studies have explored dietary interventions in CSU, but the results so far have been mixed at best. "At the end of the day, lifestyle modifications are cost-effective, noninvasive, and worth exploring, but they require proper education and guidance -- both for patients and physicians. This remains an underfunded and underresearched area, but as interest grows, we may gain clearer insights into how diet influences CSU," Friedman said. "While it's tempting to believe that cutting out a few foods might be a silver bullet, CSU is a complex, multifactorial condition. And as with most things in dermatology, there's rarely a one-size-fits-all approach." Friedman disclosed financial ties to the pharmaceutical industry. Abstract Peggy A. Wu, M.D., of the University of California Davis in Sacramento, discussed how systemic contact dermatitis (SCD) is a diagnosis to consider in the setting of a chronic, recalcitrant rash in the right clinical setting, although the diagnosis is not common. Wu discussed how SCD represents a small subset of allergic contact dermatitis (ACD) diagnoses. Like ACD, SCD is thought to be a delayed hypersensitivity reaction, and as such, reactions follow exposures in hours to days. SCD can present in a myriad of ways, including, most commonly, vesicular bilateral hand dermatitis, generalized dermatitis, and periorificial dermatitis. Frequent causes of SCD include exposure to nickel, balsam of Peru, and fragrance. The diagnosis is usually made in the setting of a chronic rash with positive patch test results to an allergen with plausible, relevant dietary sources and following topical avoidance of identified allergens. "Physicians should consider the diagnosis of SCD in the setting of a recalcitrant chronic rash with certain phenotypes (vesicular bilateral hand dermatitis, generalized dermatitis, periorificial) and positive patch test reactions to allergen(s) with a possible relevant dietary source," Wu said. "A recommended approach to SCD is to start with a one-month trial of dietary modification. Longer courses of dietary modification may benefit from working with a dietitian to maintain nutritional need." Abstract AAD: Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata TUESDAY, March 18, 2025 -- For adolescents with severe alopecia areata, baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 7 to 11 in Orlando, Florida. Read Full Text AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof FRIDAY, March 14, 2025 -- Patients with atopic dermatitis who achieve completely clear skin with tapinarof ( Vtama ) cream maintain low disease activity after about 80 days off treatment, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 7 to 11 in Orlando, Florida. Read Full Text AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata THURSDAY, March 13, 2025 -- For adults with severe alopecia areata, ivarmacitinib, a selective Janus kinase 1 inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 7 to 11 in Orlando, Florida. Read Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

14 Mar 2025

·www.drugs.com

AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof

FRIDAY, March 14, 2025 -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off treatment, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 7 to 11 in Orlando, Florida. David Rosmarin, M.D., of the Indiana University School of Medicine in Indianapolis, and colleagues conducted a 48-week open-label, long-term extension study (ADORING 3) evaluating tapinarof in 728 eligible adults and children aged 2 years or older with AD. Patients entering ADORING 3 with Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) ≥1 received tapinarof until vIGA-AD = 0 (completely clear skin). Those entering or achieving vIGA-AD = 0 discontinued tapinarof and were assessed for maintenance while off treatment. Those whose AD returned to vIGA-AD ≥2 were retreated until vIGA-AD = 0. The researchers found that at the end of the first treatment-free interval (mean, 79.8 days), 84.0 percent of patients had vIGA-AD = 2, a mean Eczema Area and Severity Index score of 3.4, and a mean weekly Peak Pruritus-Numerical Rating Scale score of 2.9. At the end of subsequent treatment-free intervals, similar low disease activity was seen. After about 80 consecutive days off treatment, a high proportion of patients demonstrated low disease activity, including itch. "These data reinforce the efficacy of Vtama cream in atopic dermatitis, including the durability of effect among patients in the study, including children as young as 2 years old," Juan Camilo Arjona Ferreira, M.D., head of research and development and chief medical officer at Organon, said in a statement. The study was funded by Dermavant Sciences (an Organon Company), which manufactures tapinarof. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Benvitimod

External Link

KEGG	Wiki	ATC	Drug Bank
-	Benvitimod	D05	DB06083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	Japan	Japan Tobacco, Inc.	24 Jun 2024
Psoriasis vulgaris	Japan	Japan Tobacco, Inc.	24 Jun 2024
Plaque psoriasis	United States	Dermavant Sciences, Inc.	23 May 2022
Psoriasis	China	Guangdong Zhonghao Pharmaceutical Co. Ltd.	29 May 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mild Atopic Dermatitis	Phase 3	China	Shanghai Thederma Pharmaceuticals Co., Ltd.	16 Apr 2025
Mild Atopic Dermatitis	Phase 3	China	Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.	16 Apr 2025
Moderate Atopic Dermatitis	Phase 3	United States	Dermavant Sciences, Inc.	01 Sep 2021
Moderate Atopic Dermatitis	Phase 3	Canada	Dermavant Sciences, Inc.	01 Sep 2021
Severe Atopic Dermatitis	Phase 3	United States	Dermavant Sciences, Inc.	01 Sep 2021
Severe Atopic Dermatitis	Phase 3	Canada	Dermavant Sciences, Inc.	01 Sep 2021
Keratoderma, Palmoplantar	Phase 2	United States	Dermavant Sciences, Inc.	30 Oct 2024
Pruritus	Phase 1	Japan	GSK Plc	27 Oct 2015
Alopecia Areata	IND Approval	China	Shanghai Thederma Pharmaceuticals Co., Ltd.	17 Apr 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05186805 (Pubmed \| Am J Clin Dermatol)	Phase 2	-	36	Tapinarof Cream 1%	skvgsvfvyh(hkvndfuofn) = no contact dermatitis bzwifyvufi (didufjkqzr ) View more	Positive	24 Mar 2025
NCT05142774 (ADORING 3, Company_Website) Manual	Phase 3	Dermatitis, Atopic	728	tapinarof	butdabwcvk(iemfpbudzn) = wndiuikhsd sdtthkayci (mthbjnhjoi ) View more	Positive	08 Mar 2025
NCT05142774 (ADORING 3, Biospace) Manual	Phase 3	Dermatitis, Atopic	728	VTAMA cream, 1%	qhnlqkejiz(mjolqttmfc) = atifubzklk isefadnavx (togtwgrzxq ) View more	Positive	25 Oct 2024
NCT05014568 \| NCT05032859 (ADORING 2, Biospace) Manual	Phase 3	Dermatitis, Atopic	813	VTAMA cream (ADORING 1)	pdnskxypnc(rmidhbtiul) = dcuvhixyum sdwyagllmw (iqrtgmxelg ) View more	Positive	24 Oct 2024
				VTAMA cream (ADORING 2)	pdnskxypnc(rmidhbtiul) = hmdbuvncci sdwyagllmw (iqrtgmxelg ) View more
ADORING 1 and 2 (ACAAI2024)	Phase 3	Dermatitis, Atopic	813	Tapinarof cream 1%	bsphglubbu(fzubdidwsk) = prxnntygvk powphbkujh (ioxawnieoa ) View more	Positive	24 Oct 2024
				Vehicle	kowxmviwky(awgtzsfval) = xnmzvburtq fpbnzoqneg (dcbhepazna ) View more
Literature Manual	Not Applicable	Pustulosis of Palms and Soles	47	Benvitimod	kylywstoer(frjeyldbgv) = fvnyytmmki vjbiwbnghc (tixfqvkvos ) View more	Positive	22 Oct 2024
NCT05680740 (DMVT-505-4001, CTgov)	Phase 4	Plaque psoriasis	34	VTAMA® (tapinarof) Cream 1%	teudutjdzf = uwzotfzpfn bytjqbmbpo (pwenporxgx, vyotfzcxjo - kmdwnrbhhr) View more	-	08 Jul 2024
NCT05014568 (ADORING 1, BusinessWire) Manual	Phase 3	Dermatitis, Atopic	407	VTAMA cream, 1% QD (ASIAN)	lbfxlllmdy(cdmdckmypy) = yvpjolummn dxkaqfdlgy (cigkbucopr ) View more	Positive	08 Mar 2024
				Vehicle QD (ASIAN)	lbfxlllmdy(cdmdckmypy) = fsbbqthjos dxkaqfdlgy (cigkbucopr ) View more
NCT05032859 (ADORING 2, BusinessWire) Manual	Phase 3	Dermatitis, Atopic	406	VTAMA cream, 1% QD (ASIAN)	zkhoiolsuc(fbnivepwts) = mulgaxjdxn wblfokmnlw (hbhnzcnlma ) View more	Positive	08 Mar 2024
				Vehicle QD (ASIAN)	zkhoiolsuc(fbnivepwts) = xrwkmmnppz wblfokmnlw (hbhnzcnlma ) View more
AAAAI2024	Phase 3	Dermatitis, Atopic	-	Tapinarof cream 1%	salonqnkyh(wqexgaisqh) = kbxdzossfo sspbcnwknq (oxmyytnyvs )	Positive	23 Feb 2024
				Vehicle	salonqnkyh(wqexgaisqh) = lglcqsitrg sspbcnwknq (oxmyytnyvs )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis